Investing.com - Nabriva (NASDAQ:NBRV) Therapeutics reported on Tuesday third quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
Nabriva Therapeutics announced earnings per share of $-0.21 on revenue of $8.9M. Analysts polled by Investing.com anticipated EPS of $-0.22 on revenue of $8.9M.
Nabriva Therapeutics shares are down 45.45% from the beginning of the year, still down 72.78% from its 52 week high of $4.85 set on November 13, 2020. They are under-performing the Nasdaq which is up 23.26% from the start of the year.
Nabriva Therapeutics follows other major Healthcare sector earnings this month
Nabriva Therapeutics's report follows an earnings beat by J&J on October 19, who reported EPS of $2.6 on revenue of $23.34B, compared to forecasts EPS of $2.35 on revenue of $23.64B.
Pfizer had beat expectations on November 2 with third quarter EPS of $1.34 on revenue of $24.09B, compared to forecast for EPS of $1.08 on revenue of $22.58B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar